SEQSTER CEO Ardy Arianpour Named to PharmaVoice 100 for Innovation in Life Sciences for a Second Consecutive Year
2024年10月8日 - 9:45PM
ビジネスワイヤ(英語)
Life Sciences Leader Honored for Driving Real
World Data, Patient-Centric Registries, and Global Pharma
Partnerships
SEQSTER PDM Inc. ("SEQSTER"), the leading healthcare technology
company, today announced that CEO and Co-Founder Ardy Arianpour has
been named to the prestigious 2024 PharmaVoice 100, marking the
second consecutive year he has received this recognition for his
inspirational leadership and groundbreaking work in life
sciences.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20241008712158/en/
Ardy Arianpour has been named to the
prestigious 2024 PharmaVoice 100, a recognition of the 100 most
inspiring people in the life sciences industry. (Graphic: Business
Wire)
Arianpour joins an elite group of 100 industry visionaries
honored for their contributions to innovation, patient engagement,
and driving advancements in life sciences. This year’s PharmaVoice
100 celebrates professionals across the life sciences industry,
including trailblazers in research, clinical trials, patient
advocacy, technology, and commercialization.
"Receiving this recognition for the second year in a row is
incredibly meaningful as it highlights the milestones SEQSTER has
achieved," said Arianpour. "We are integrating technology and the
life sciences industry with the broader healthcare ecosystem to
drive innovation and create scalable impact for patient lives. From
powering patient registries to launching innovative platforms like
1-Click Records™ for rapid EHR data retrieval and CoRD™ data
refinery for researchers, we have made significant strides in
breaking down data silos and advancing the life sciences industry.
Our new strategic partnerships with global pharma companies are
transforming patient recruitment and delivering valuable AI-driven
insights. These initiatives are at the heart of our mission to
enhance patient outcomes and accelerate the pace of clinical
research."
Throughout a distinguished 20-year career in the life sciences
sector, Ardy Arianpour has been at the forefront of healthcare
innovation, driving patient-centric advancements and groundbreaking
technologies. Prior to founding SEQSTER, Arianpour had the
privilege of launching various clinical and consumer-based genetic
tests while serving as Senior Vice President and General Manager of
Genomics at Ambry Genetics, a company that was acquired by Konica
for $1 billion in 2017. One of Arianpour’s significant
contributions was his pivotal role in the landmark 2013 SCOTUS
decision that eliminated gene patents, democratizing access to
genetic testing. The introduction of BRCA testing, in particular,
had a profound impact on patients, caregivers and their families
nationwide.
Arianpour is a globally recognized pioneer in life sciences and
healthcare, earning accolades such as the American Heart
Association Health Tech Award (2018), Top 40 Healthcare Transformer
by Medical Marketing & Media (2019), and Med Tech World Rising
Star (2022). Ardy was also named to the PharmaVoice 100 in 2023.
His impact on life sciences, healthcare, and technology is further
underscored by his recent appointments to the advisory boards of
Inside Precision Medicine and the Fleet Science Center.
PharmaVoice100 honorees are selected from a pool of nominations
submitted by readers and colleagues, evaluated by the PharmaVoice
team, then categorized into 10 distinct groups: Standout Leaders,
Cancer Care Visionaries, Cardiometabolic All-Stars, Trailblazers,
Biotech Pathfinders, Rare Disease Warriors, Tech and AI Wizards,
Clinical Trial Pros, Patient Champions, and Cell and Gene Therapy
Pioneers. Each winner represents the transformative impact of the
pharmaceutical industry in their own unique way.
“These honorees are inspirations. Their teams look to them for
guidance, their patients for support, and their organizations for
direction. Each winner represents progress toward a healthier
future for everyone that is bolstered by science and technological
advancements. We are excited to recognize their contributions
through this annual list,” said Meagan Parrish, lead editor of
PharmaVoice.
Since 2005, the PharmaVoice 100 has become one of the
publication’s most anticipated features. From academia and
nonprofits to Big Pharma, startups and tech companies, it is the
only awards program in the industry that honors individuals from
all sectors of life sciences. These honorees, from the clinic to
the C-suite, are making meaningful contributions to their fields
and striving to improve outcomes for patients around the world.
Arianpour’s inclusion for the second consecutive year underscores
his lasting impact on the life sciences industry and his continued
commitment to improving healthcare through patient-centric
innovation.
About SEQSTER
SEQSTER is the leading healthcare technology company that breaks
down health data silos at scale. Its enterprise operating system
aggregates disparate health data sources into a single, 360-degree
view of a patient in real-time, solving a multitude of challenges
for life sciences, patient engagement and data
interoperability.
SEQSTER has nationwide coverage of EHRs from hospitals and
medical groups, genomic DNA, wearables, pharmacy and social
determinants of health data. Through its customizable white-label
approach, SEQSTER provides accelerated access to de-identified,
tokenized, real-time data and comprehensive curated data to address
critical needs across the healthcare continuum.
SEQSTER is privately held and headquartered in San Diego.
To learn more about the SEQSTER Operating System for Clinical
Studies, Patient Registries and the Digital Front Door, please
contact us at info@seqster.com or visit www.seqster.com.
About PharmaVoice
PharmaVoice is a leading industry publication operated by
Industry Dive. Our stories deliver the most important voices and
ideas in the life sciences to industry leaders.
About Industry Dive
Industry Dive, an Informa business, is a leading business
journalism company. Over 14 million decision-makers across 20+
competitive industries rely on our exclusive insight and analysis
delivered through more than 30 publications.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241008712158/en/
Bill Douglass SEQSTER press@seqster.com